Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a milk protein shield kidneys from diabetes damage?

NCT ID NCT07764991

Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial tests whether a daily 250 mg supplement of lactoferrin, a protein found in milk, can improve kidney health in people with type 2 diabetes and chronic kidney disease. The study will compare lactoferrin against a placebo, alongside standard diabetes care, to see if it reduces protein in the urine and improves kidney function and blood sugar control. Participants are adults with stage 3 or 4 chronic kidney disease and elevated albuminuria.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lactoferrin, a protein found in milk, taken as a 250 mg daily supplement
What this could lead to
If it works, lactoferrin could become a simple, natural supplement to help slow kidney damage and improve blood sugar control in people with diabetic nephropathy.
What could go wrong
This is a small, early-stage trial, so results may not be conclusive. The supplement's benefits are uncertain, and it may not work for everyone or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Type II diabetic patients with CKD stage 3 (eGFR = 30 - 59 ml/min/1.73m2) or stage 4 (eGFR 15-29 ml/min/1.73m2) * Urinary albumin/Creatinine ratio (UACR): moderately and severely increased albuminuria (\> 30 mg/g) * Stable standard therapy for at least three months prior to inclusion in the study. * Life expectancy \>12 months. Exclusion Criteria: * Participation in other interventional trials * Current or previous treatment with LF supplements at least three months before inclusion. * Kidney donor or recipient * Pregnancy or breastfeeding * Active malignancy * Poor adherence potential (e.g. cognitive impairment, psychiatric instability) * Known intolerance or allergy to lactoferrin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic nephropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ain Shams University Hospitals

    RECRUITING

    Cairo, 11566, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.